Vir Biotechnology, Inc. (VIR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 94.96M USD | Liabilities, Current |
| Cash and equivalents | 278.73M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 249.86M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $94.96M | $278.73M | $249.86M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $73.56M | $274.16M | $196.28M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $92.81M | $232.19M | $228.75M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $75.22M | $170.08M | $327.75M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $105.00M | $211.10M | $387.64M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $137.29M | $273.57M | $517.37M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $119.66M | $222.95M | $678.05M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $117.16M | $168.35M | $740.61M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $96.41M | $296.86M | $849.83M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $94.07M | $160.71M | $985.13M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $175.41M | $241.58M | $1.27B | (m) | (m) | (m) |
| 2023-09-30 | (m) | $165.05M | $452.10M | $1.23B | (m) | (m) | (m) |
| 2023-06-30 | (m) | $225.62M | $666.95M | $1.17B | (m) | (m) | (m) |
| 2023-03-31 | (m) | $485.29M | $824.91M | $1.41B | (m) | (m) | (m) |
| 2022-12-31 | $2.37B | $511.03M | $848.63M | $1.52B | $0.00 | (m) | 4.64× |
| 2022-09-30 | $2.32B | $308.20M | $963.74M | $1.36B | $0.00 | (m) | 7.54× |
| 2022-06-30 | $2.17B | $477.87M | $1.51B | $654.11M | $7.00M | (m) | 4.53× |
| 2022-03-31 | $2.44B | $702.36M | $812.36M | $399.83M | $1.22B | (m) | 3.47× |
| 2021-12-31 | $1.34B | $341.24M | $347.81M | $217.18M | $773.08M | (m) | 3.92× |
| 2021-09-30 | $863.08M | $233.72M | $714.52M | $55.56M | $93.00M | (m) | 3.69× |
| 2021-06-30 | (m) | $146.02M | $741.95M | $84.11M | (m) | (m) | (m) |
| 2021-03-31 | $845.53M | $361.10M | $521.40M | $211.64M | $112.50M | (m) | 2.34× |
| 2020-12-31 | (m) | $99.06M | $436.57M | $300.29M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $77.00M | $462.52M | $364.07M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $54.94M | $371.78M | $180.60M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $56.40M | $168.42M | $187.19M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $59.21M | $109.33M | $274.10M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $44.32M | $93.70M | $226.51M | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $80.68M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $64.72M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $39.91M | $47.60M | $50.84M | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | $47.67M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $187.92M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |